AbbVie Inc. (ABBV)の価格はいくらですか

AbbVie Inc. (ABBV)の価格は$265.95です

AbbVie Inc. (ABBV)の時価総額は何ですか

AbbVie Inc. (ABBV)の時価総額は$469.88Bです

AbbVie Inc.（ABBV）発行済株式数

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

年	発行済株式数	変化
2026 (TTM)	1.77B	-1.10%
2025	1.79B	1.23%
2024	1.77B	0.06%
2023	1.77B	-0.17%
2022	1.77B	0.06%
2021	1.77B	6.18%
2020	1.67B	12.56%
2019	1.48B	-3.89%
2018	1.54B	-3.45%
2017	1.60B	-1.60%
2016	1.62B	-0.18%
2015	1.63B	1.88%
2014	1.60B	0.38%
2013	1.59B	0.76%
2012	1.58B	-2.41%
2011	1.62B	0.00%
2010	1.62B	0.00%
2009	1.62B	0.00%

年

発行済株式数

変化

2026 (TTM)

1.77B

-1.10%

2025

1.79B

1.23%

2024

1.77B

0.06%

2023

1.77B

-0.17%

2022

1.77B

0.06%

2021

1.77B

6.18%

2020

1.67B

12.56%

2019

1.48B

-3.89%

2018

1.54B

-3.45%

2017

1.60B

-1.60%

2016

1.62B

-0.18%

2015

1.63B

1.88%

2014

1.60B

0.38%

2013

1.59B

0.76%

2012

1.58B

-2.41%

2011

1.62B

0.00%

2010

1.62B

0.00%

2009

1.62B

0.00%

企業	発行済株式数	差	国
Eli Lilly and Company LLY.US	892.40M	-49.61%	US
Johnson & Johnson JNJ.US	2.44B	37.78%	US
Roche Holding AG RO.SW	796.00M	-55.05%	CH
Merck & Co., Inc. MRK.US	0.00	-100.00%	US
Novartis AG NOVN.SW	1.91B	8.02%	CH

企業

発行済株式数

差

国